Market cap
$27 Mln
Recently Viewed
Clear All$4.91
$-0.30
(-5.76%)
As on 17-Feb-2023 09:30EDT
Market cap
$27 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
0.8
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$-16 Mln
ROE
-0.3 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
0.4
Debt to Equity
0
Book Value
$--
EPS
$--
Face value
--
Shares outstanding
62,355,400
CFO
$-349.61 Mln
EBITDA
$-356.63 Mln
Net Profit
$-360.00 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Idera Pharmaceuticals (IDRA)
| 1,302.9 | -46.7 | 1,263.9 | 843.9 | 45.6 | -20.5 | -0.7 |
|
BSE Sensex*
| -9.2 | 4.5 | -6.1 | -2.9 | 8.2 | 9.5 | 11.4 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
2016
|
|---|---|---|---|---|---|---|---|
|
Idera Pharmaceuticals (IDRA)
| -38.5 | -84.5 | 101.6 | -34.3 | -83.4 | 40.7 | -51.5 |
|
S&P Small-Cap 600
| -17.4 | 25.3 | 9.6 | 20.9 | -9.7 | 11.7 | 24.7 |
|
BSE Sensex
| 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 | 1.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Idera Pharmaceuticals (IDRA)
|
4.9 | 26.5 | 0.1 | -16.7 | -46,093.9 | -71.7 | -- | 0.8 |
| 23.9 | 58.5 | 0.0 | -43.4 | -- | -40.2 | -- | 0.7 |
Idera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for rare disease indications in the United States. It offers Tilsotolimod (IMO-2125), a synthetic phosphorothioate... oligonucleotide that acts as a direct agonist of TLR9 to stimulate the immune systems and for treating solid tumors, squamous cell carcinoma of the head and neck, and colorectal cancer. The company has a collaboration agreement with Bristol-Meyers Squibb. Idera Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Exton, Pennsylvania. Read more
Chief Financial Officer
Mr. John J. Kirby CPA
Chief Financial Officer
Mr. John J. Kirby CPA
Headquarters
Exton, PA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Idera Pharmaceuticals Inc (IDRA) is $4.91 (NASDAQ) as of 17-Feb-2023 09:30 EDT. Idera Pharmaceuticals Inc (IDRA) has given a return of 45.62% in the last 3 years.
Since, TTM earnings of Idera Pharmaceuticals Inc (IDRA) is negative, P/E ratio is not available.
The P/B ratio of Idera Pharmaceuticals Inc (IDRA) is 0.84 times as on 17-Feb-2023, a 84 discount to its peers’ median range of 5.16 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2021
|
--
|
--
|
|
2020
|
--
|
--
|
|
2019
|
--
|
--
|
|
2018
|
--
|
--
|
|
2017
|
--
|
--
|
The 52-week high and low of Idera Pharmaceuticals Inc (IDRA) are Rs -- and Rs -- as of 28-Apr-2026.
Idera Pharmaceuticals Inc (IDRA) has a market capitalisation of $ 27 Mln as on 17-Feb-2023. As per SEBI classification, it is a Small Cap company.
Before investing in Idera Pharmaceuticals Inc (IDRA), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.